Related Experiment Video

Updated: Jul 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases

Nadia Rucci1, Maria Susa, Anna Teti

  • 1Department of Experimental Medicine, University of L'Aquila, Via Vetoio - Coppito 2, 67100 L'Aquila, Italy.

Anti-Cancer Agents in Medicinal Chemistry
|April 9, 2008
PubMed

Insights

Src inhibitors show promise for treating bone loss and cancer metastasis. These drugs target c-Src (a proto-oncogene) to inhibit osteoclasts and tumor cells, potentially disrupting bone microenvironments and reducing disease progression.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Biology

Background:

  • c-Src is a proto-oncogene implicated in cancer development and invasion.
  • c-Src is vital for osteoclast function, regulating bone homeostasis.
  • Dysregulation of c-Src contributes to bone loss and skeletal metastases.

Purpose of the Study:

  • To evaluate c-Src inhibitors as a therapeutic strategy for cancers and bone diseases.
  • To investigate the potential of c-Src inhibition in managing skeletal metastases and osteoporosis.
  • To explore the dual action of c-Src inhibitors on tumor cells and bone resorption.

Main Methods:

  • Preclinical studies using pyrrolo-pyrimidine and purine-based c-Src inhibitors (e.g., CGP77675, CGP76030, AP23451).
  • Evaluation of dual c-Src/Bcr-ABL inhibitors (e.g., AZD0530) in Phase I clinical trials.
  • Assessment of therapeutic effects in animal models of bone loss and bone metastasis.

Main Results:

  • CGP77675 and CGP76030 prevented bone loss in animal models.
  • AZD0530 demonstrated promising results in reducing bone resorption during clinical trials.
  • CGP76030 reduced osteolytic lesions and visceral metastases in a bone metastasis model.
  • AP23451, AP22408, and AP23236 showed efficacy in reducing bone metastases in preclinical studies.

Conclusions:

  • c-Src inhibitors represent a promising therapeutic avenue for bone metastatic disease.
  • Targeting c-Src offers a dual approach to combatting cancer and bone loss.
  • Further development of c-Src inhibitors could lead to innovative treatments for osteoporosis and metastatic cancers.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...